A combination povidone-iodine 0.4%/dexamethasone 0.1% ophthalmic suspension in the treatment of adenoviral conjunctivitis

Introduction The objective of this pilot study was to determine the preliminary efficacy of a novel ophthalmic suspension containing povidone-iodine 0.4% and dexamethasone 0.1% in the treatment of adenoviral conjunctivitis. Methods A prospective, open-label, single-armed, phase II clinical trial in...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Advances in therapy 2009-08, Vol.26 (8), p.776-783
Hauptverfasser: Pelletier, J. S., Stewart, K., Trattler, W., Ritterband, D. C., Braverman, S., Samson, C. M., Liang, B., Capriotti, J. A.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 783
container_issue 8
container_start_page 776
container_title Advances in therapy
container_volume 26
creator Pelletier, J. S.
Stewart, K.
Trattler, W.
Ritterband, D. C.
Braverman, S.
Samson, C. M.
Liang, B.
Capriotti, J. A.
description Introduction The objective of this pilot study was to determine the preliminary efficacy of a novel ophthalmic suspension containing povidone-iodine 0.4% and dexamethasone 0.1% in the treatment of adenoviral conjunctivitis. Methods A prospective, open-label, single-armed, phase II clinical trial in humans. Eligible patients with the clinical signs and symptoms of acute conjunctivitis who tested positive for adenoviral antigen by Rapid Pathogen Screening (RPS) Adeno Detector™ were enrolled in a single treatment arm consisting of a combination povidone-iodine 0.4%/dexamethasone 0.1% sterile ophthalmic suspension given four times daily for a minimum of 5 days. RPS Adeno Detector testing was performed at baseline and at each follow-up visit along with ocular fluid sampling by conjunctival swabs. Subsequent analysis performed on all swabs included both adenoviral titer by quantitative polymerase chain reaction (qPCR) and cell culture with confirmatory immunofluorescence (CC-IFA). The primary endpoint was clinical resolution of conjunctival injection and discharge. Secondary measures included reduction of qPCR titers and eradication of infectious virus as determined by CC-IFA. Results A total of nine eyes of six patients with clinical signs and symptoms of acute viral conjunctivitis and a positive RPS Adeno Detector test result were enrolled in the study. In eight/nine eyes enrolled in the study, clinical resolution was observed by day 3 or day 4. In six/six eyes with detectable adenovirus by qPCR, significant reduction in viral titer was seen by day 3, day 4, or day 5. In five/six eyes with infectious virus confirmed by CC-IFA at enrollment, elimination of infectivity was achieved by day 4 or day 5. One patient was lost to follow-up. Conclusions An ophthalmic suspension containing povidone-iodine 0.4% and dexamethasone 0.1% may be a useful agent in the treatment of acute RPS Adeno Detector-positive conjunctivitis. A further placebo-controlled study with a larger number of patients is warranted.
doi_str_mv 10.1007/s12325-009-0062-1
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_734220219</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>734220219</sourcerecordid><originalsourceid>FETCH-LOGICAL-c409t-c0eaa5b8815be329f972c3b535ba36db00eb0513e2e70f37fdd8f88ec570a3a93</originalsourceid><addsrcrecordid>eNp9kEFP3DAQha2KqizQH8Cl8gVxCozteJ0cEWoBCYlLK3GzHGfCepXYwXYQ_Pt6uyv1xuHJ8vi9N_JHyDmDKwagrhPjgssKoC1a84p9ISvWrGVVxI_IClTNKi6a52NyktIWgIOSzTdyzFol1zWTK_JxQ22YOudNdsHTOby5PnisXOidRwpX9cV1j-9mwrwxKfwbsQsa5k25j5OzNC1pRp92aedp3iDNEU2e0GcaBmp69KU0mrEs8tvF2-zeXHbpjHwdzJjw--E8JX9-_fx9e189Pt093N48VraGNlcW0BjZNQ2THQreDq3iVnRSyM6Idd8BYAeSCeSoYBBq6PtmaBq0UoERphWn5HLfO8fwumDKenLJ4jgaj2FJWomac-Bs52R7p40hpYiDnqObTPzQDPQOuN4D1wW43gHXrGR-HNqXbsL-f-JAuBj43pDKk3_BqLdhib78-JPWv3UojSo</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>734220219</pqid></control><display><type>article</type><title>A combination povidone-iodine 0.4%/dexamethasone 0.1% ophthalmic suspension in the treatment of adenoviral conjunctivitis</title><source>MEDLINE</source><source>SpringerLink Journals - AutoHoldings</source><creator>Pelletier, J. S. ; Stewart, K. ; Trattler, W. ; Ritterband, D. C. ; Braverman, S. ; Samson, C. M. ; Liang, B. ; Capriotti, J. A.</creator><creatorcontrib>Pelletier, J. S. ; Stewart, K. ; Trattler, W. ; Ritterband, D. C. ; Braverman, S. ; Samson, C. M. ; Liang, B. ; Capriotti, J. A.</creatorcontrib><description>Introduction The objective of this pilot study was to determine the preliminary efficacy of a novel ophthalmic suspension containing povidone-iodine 0.4% and dexamethasone 0.1% in the treatment of adenoviral conjunctivitis. Methods A prospective, open-label, single-armed, phase II clinical trial in humans. Eligible patients with the clinical signs and symptoms of acute conjunctivitis who tested positive for adenoviral antigen by Rapid Pathogen Screening (RPS) Adeno Detector™ were enrolled in a single treatment arm consisting of a combination povidone-iodine 0.4%/dexamethasone 0.1% sterile ophthalmic suspension given four times daily for a minimum of 5 days. RPS Adeno Detector testing was performed at baseline and at each follow-up visit along with ocular fluid sampling by conjunctival swabs. Subsequent analysis performed on all swabs included both adenoviral titer by quantitative polymerase chain reaction (qPCR) and cell culture with confirmatory immunofluorescence (CC-IFA). The primary endpoint was clinical resolution of conjunctival injection and discharge. Secondary measures included reduction of qPCR titers and eradication of infectious virus as determined by CC-IFA. Results A total of nine eyes of six patients with clinical signs and symptoms of acute viral conjunctivitis and a positive RPS Adeno Detector test result were enrolled in the study. In eight/nine eyes enrolled in the study, clinical resolution was observed by day 3 or day 4. In six/six eyes with detectable adenovirus by qPCR, significant reduction in viral titer was seen by day 3, day 4, or day 5. In five/six eyes with infectious virus confirmed by CC-IFA at enrollment, elimination of infectivity was achieved by day 4 or day 5. One patient was lost to follow-up. Conclusions An ophthalmic suspension containing povidone-iodine 0.4% and dexamethasone 0.1% may be a useful agent in the treatment of acute RPS Adeno Detector-positive conjunctivitis. A further placebo-controlled study with a larger number of patients is warranted.</description><identifier>ISSN: 0741-238X</identifier><identifier>EISSN: 1865-8652</identifier><identifier>DOI: 10.1007/s12325-009-0062-1</identifier><identifier>PMID: 19756415</identifier><language>eng</language><publisher>Heidelberg: Springer Healthcare Communications</publisher><subject>Acute Disease ; Adenovirus Infections, Human - diagnosis ; Adenovirus Infections, Human - drug therapy ; Adenovirus Infections, Human - virology ; Anti-Infective Agents, Local - therapeutic use ; Anti-Inflammatory Agents - therapeutic use ; Cardiology ; Conjunctivitis, Viral - diagnosis ; Conjunctivitis, Viral - drug therapy ; Conjunctivitis, Viral - virology ; Dexamethasone - therapeutic use ; Drug Administration Schedule ; Drug Combinations ; Endocrinology ; Fluorescent Antibody Technique ; Health technology assessment ; Humans ; Internal Medicine ; Medicine ; Medicine &amp; Public Health ; Oncology ; Ophthalmic Solutions ; Original Research ; Pharmacology/Toxicology ; Pilot Projects ; Polymerase Chain Reaction ; Povidone-Iodine - therapeutic use ; Prospective Studies ; Rheumatology ; Treatment Outcome</subject><ispartof>Advances in therapy, 2009-08, Vol.26 (8), p.776-783</ispartof><rights>Springer Healthcare Communications 2009</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c409t-c0eaa5b8815be329f972c3b535ba36db00eb0513e2e70f37fdd8f88ec570a3a93</citedby><cites>FETCH-LOGICAL-c409t-c0eaa5b8815be329f972c3b535ba36db00eb0513e2e70f37fdd8f88ec570a3a93</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s12325-009-0062-1$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s12325-009-0062-1$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,780,784,27924,27925,41488,42557,51319</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/19756415$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Pelletier, J. S.</creatorcontrib><creatorcontrib>Stewart, K.</creatorcontrib><creatorcontrib>Trattler, W.</creatorcontrib><creatorcontrib>Ritterband, D. C.</creatorcontrib><creatorcontrib>Braverman, S.</creatorcontrib><creatorcontrib>Samson, C. M.</creatorcontrib><creatorcontrib>Liang, B.</creatorcontrib><creatorcontrib>Capriotti, J. A.</creatorcontrib><title>A combination povidone-iodine 0.4%/dexamethasone 0.1% ophthalmic suspension in the treatment of adenoviral conjunctivitis</title><title>Advances in therapy</title><addtitle>Adv Therapy</addtitle><addtitle>Adv Ther</addtitle><description>Introduction The objective of this pilot study was to determine the preliminary efficacy of a novel ophthalmic suspension containing povidone-iodine 0.4% and dexamethasone 0.1% in the treatment of adenoviral conjunctivitis. Methods A prospective, open-label, single-armed, phase II clinical trial in humans. Eligible patients with the clinical signs and symptoms of acute conjunctivitis who tested positive for adenoviral antigen by Rapid Pathogen Screening (RPS) Adeno Detector™ were enrolled in a single treatment arm consisting of a combination povidone-iodine 0.4%/dexamethasone 0.1% sterile ophthalmic suspension given four times daily for a minimum of 5 days. RPS Adeno Detector testing was performed at baseline and at each follow-up visit along with ocular fluid sampling by conjunctival swabs. Subsequent analysis performed on all swabs included both adenoviral titer by quantitative polymerase chain reaction (qPCR) and cell culture with confirmatory immunofluorescence (CC-IFA). The primary endpoint was clinical resolution of conjunctival injection and discharge. Secondary measures included reduction of qPCR titers and eradication of infectious virus as determined by CC-IFA. Results A total of nine eyes of six patients with clinical signs and symptoms of acute viral conjunctivitis and a positive RPS Adeno Detector test result were enrolled in the study. In eight/nine eyes enrolled in the study, clinical resolution was observed by day 3 or day 4. In six/six eyes with detectable adenovirus by qPCR, significant reduction in viral titer was seen by day 3, day 4, or day 5. In five/six eyes with infectious virus confirmed by CC-IFA at enrollment, elimination of infectivity was achieved by day 4 or day 5. One patient was lost to follow-up. Conclusions An ophthalmic suspension containing povidone-iodine 0.4% and dexamethasone 0.1% may be a useful agent in the treatment of acute RPS Adeno Detector-positive conjunctivitis. A further placebo-controlled study with a larger number of patients is warranted.</description><subject>Acute Disease</subject><subject>Adenovirus Infections, Human - diagnosis</subject><subject>Adenovirus Infections, Human - drug therapy</subject><subject>Adenovirus Infections, Human - virology</subject><subject>Anti-Infective Agents, Local - therapeutic use</subject><subject>Anti-Inflammatory Agents - therapeutic use</subject><subject>Cardiology</subject><subject>Conjunctivitis, Viral - diagnosis</subject><subject>Conjunctivitis, Viral - drug therapy</subject><subject>Conjunctivitis, Viral - virology</subject><subject>Dexamethasone - therapeutic use</subject><subject>Drug Administration Schedule</subject><subject>Drug Combinations</subject><subject>Endocrinology</subject><subject>Fluorescent Antibody Technique</subject><subject>Health technology assessment</subject><subject>Humans</subject><subject>Internal Medicine</subject><subject>Medicine</subject><subject>Medicine &amp; Public Health</subject><subject>Oncology</subject><subject>Ophthalmic Solutions</subject><subject>Original Research</subject><subject>Pharmacology/Toxicology</subject><subject>Pilot Projects</subject><subject>Polymerase Chain Reaction</subject><subject>Povidone-Iodine - therapeutic use</subject><subject>Prospective Studies</subject><subject>Rheumatology</subject><subject>Treatment Outcome</subject><issn>0741-238X</issn><issn>1865-8652</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2009</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kEFP3DAQha2KqizQH8Cl8gVxCozteJ0cEWoBCYlLK3GzHGfCepXYwXYQ_Pt6uyv1xuHJ8vi9N_JHyDmDKwagrhPjgssKoC1a84p9ISvWrGVVxI_IClTNKi6a52NyktIWgIOSzTdyzFol1zWTK_JxQ22YOudNdsHTOby5PnisXOidRwpX9cV1j-9mwrwxKfwbsQsa5k25j5OzNC1pRp92aedp3iDNEU2e0GcaBmp69KU0mrEs8tvF2-zeXHbpjHwdzJjw--E8JX9-_fx9e189Pt093N48VraGNlcW0BjZNQ2THQreDq3iVnRSyM6Idd8BYAeSCeSoYBBq6PtmaBq0UoERphWn5HLfO8fwumDKenLJ4jgaj2FJWomac-Bs52R7p40hpYiDnqObTPzQDPQOuN4D1wW43gHXrGR-HNqXbsL-f-JAuBj43pDKk3_BqLdhib78-JPWv3UojSo</recordid><startdate>20090801</startdate><enddate>20090801</enddate><creator>Pelletier, J. S.</creator><creator>Stewart, K.</creator><creator>Trattler, W.</creator><creator>Ritterband, D. C.</creator><creator>Braverman, S.</creator><creator>Samson, C. M.</creator><creator>Liang, B.</creator><creator>Capriotti, J. A.</creator><general>Springer Healthcare Communications</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20090801</creationdate><title>A combination povidone-iodine 0.4%/dexamethasone 0.1% ophthalmic suspension in the treatment of adenoviral conjunctivitis</title><author>Pelletier, J. S. ; Stewart, K. ; Trattler, W. ; Ritterband, D. C. ; Braverman, S. ; Samson, C. M. ; Liang, B. ; Capriotti, J. A.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c409t-c0eaa5b8815be329f972c3b535ba36db00eb0513e2e70f37fdd8f88ec570a3a93</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2009</creationdate><topic>Acute Disease</topic><topic>Adenovirus Infections, Human - diagnosis</topic><topic>Adenovirus Infections, Human - drug therapy</topic><topic>Adenovirus Infections, Human - virology</topic><topic>Anti-Infective Agents, Local - therapeutic use</topic><topic>Anti-Inflammatory Agents - therapeutic use</topic><topic>Cardiology</topic><topic>Conjunctivitis, Viral - diagnosis</topic><topic>Conjunctivitis, Viral - drug therapy</topic><topic>Conjunctivitis, Viral - virology</topic><topic>Dexamethasone - therapeutic use</topic><topic>Drug Administration Schedule</topic><topic>Drug Combinations</topic><topic>Endocrinology</topic><topic>Fluorescent Antibody Technique</topic><topic>Health technology assessment</topic><topic>Humans</topic><topic>Internal Medicine</topic><topic>Medicine</topic><topic>Medicine &amp; Public Health</topic><topic>Oncology</topic><topic>Ophthalmic Solutions</topic><topic>Original Research</topic><topic>Pharmacology/Toxicology</topic><topic>Pilot Projects</topic><topic>Polymerase Chain Reaction</topic><topic>Povidone-Iodine - therapeutic use</topic><topic>Prospective Studies</topic><topic>Rheumatology</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Pelletier, J. S.</creatorcontrib><creatorcontrib>Stewart, K.</creatorcontrib><creatorcontrib>Trattler, W.</creatorcontrib><creatorcontrib>Ritterband, D. C.</creatorcontrib><creatorcontrib>Braverman, S.</creatorcontrib><creatorcontrib>Samson, C. M.</creatorcontrib><creatorcontrib>Liang, B.</creatorcontrib><creatorcontrib>Capriotti, J. A.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Advances in therapy</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Pelletier, J. S.</au><au>Stewart, K.</au><au>Trattler, W.</au><au>Ritterband, D. C.</au><au>Braverman, S.</au><au>Samson, C. M.</au><au>Liang, B.</au><au>Capriotti, J. A.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>A combination povidone-iodine 0.4%/dexamethasone 0.1% ophthalmic suspension in the treatment of adenoviral conjunctivitis</atitle><jtitle>Advances in therapy</jtitle><stitle>Adv Therapy</stitle><addtitle>Adv Ther</addtitle><date>2009-08-01</date><risdate>2009</risdate><volume>26</volume><issue>8</issue><spage>776</spage><epage>783</epage><pages>776-783</pages><issn>0741-238X</issn><eissn>1865-8652</eissn><abstract>Introduction The objective of this pilot study was to determine the preliminary efficacy of a novel ophthalmic suspension containing povidone-iodine 0.4% and dexamethasone 0.1% in the treatment of adenoviral conjunctivitis. Methods A prospective, open-label, single-armed, phase II clinical trial in humans. Eligible patients with the clinical signs and symptoms of acute conjunctivitis who tested positive for adenoviral antigen by Rapid Pathogen Screening (RPS) Adeno Detector™ were enrolled in a single treatment arm consisting of a combination povidone-iodine 0.4%/dexamethasone 0.1% sterile ophthalmic suspension given four times daily for a minimum of 5 days. RPS Adeno Detector testing was performed at baseline and at each follow-up visit along with ocular fluid sampling by conjunctival swabs. Subsequent analysis performed on all swabs included both adenoviral titer by quantitative polymerase chain reaction (qPCR) and cell culture with confirmatory immunofluorescence (CC-IFA). The primary endpoint was clinical resolution of conjunctival injection and discharge. Secondary measures included reduction of qPCR titers and eradication of infectious virus as determined by CC-IFA. Results A total of nine eyes of six patients with clinical signs and symptoms of acute viral conjunctivitis and a positive RPS Adeno Detector test result were enrolled in the study. In eight/nine eyes enrolled in the study, clinical resolution was observed by day 3 or day 4. In six/six eyes with detectable adenovirus by qPCR, significant reduction in viral titer was seen by day 3, day 4, or day 5. In five/six eyes with infectious virus confirmed by CC-IFA at enrollment, elimination of infectivity was achieved by day 4 or day 5. One patient was lost to follow-up. Conclusions An ophthalmic suspension containing povidone-iodine 0.4% and dexamethasone 0.1% may be a useful agent in the treatment of acute RPS Adeno Detector-positive conjunctivitis. A further placebo-controlled study with a larger number of patients is warranted.</abstract><cop>Heidelberg</cop><pub>Springer Healthcare Communications</pub><pmid>19756415</pmid><doi>10.1007/s12325-009-0062-1</doi><tpages>8</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0741-238X
ispartof Advances in therapy, 2009-08, Vol.26 (8), p.776-783
issn 0741-238X
1865-8652
language eng
recordid cdi_proquest_miscellaneous_734220219
source MEDLINE; SpringerLink Journals - AutoHoldings
subjects Acute Disease
Adenovirus Infections, Human - diagnosis
Adenovirus Infections, Human - drug therapy
Adenovirus Infections, Human - virology
Anti-Infective Agents, Local - therapeutic use
Anti-Inflammatory Agents - therapeutic use
Cardiology
Conjunctivitis, Viral - diagnosis
Conjunctivitis, Viral - drug therapy
Conjunctivitis, Viral - virology
Dexamethasone - therapeutic use
Drug Administration Schedule
Drug Combinations
Endocrinology
Fluorescent Antibody Technique
Health technology assessment
Humans
Internal Medicine
Medicine
Medicine & Public Health
Oncology
Ophthalmic Solutions
Original Research
Pharmacology/Toxicology
Pilot Projects
Polymerase Chain Reaction
Povidone-Iodine - therapeutic use
Prospective Studies
Rheumatology
Treatment Outcome
title A combination povidone-iodine 0.4%/dexamethasone 0.1% ophthalmic suspension in the treatment of adenoviral conjunctivitis
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-06T20%3A16%3A13IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=A%20combination%20povidone-iodine%200.4%25/dexamethasone%200.1%25%20ophthalmic%20suspension%20in%20the%20treatment%20of%20adenoviral%20conjunctivitis&rft.jtitle=Advances%20in%20therapy&rft.au=Pelletier,%20J.%20S.&rft.date=2009-08-01&rft.volume=26&rft.issue=8&rft.spage=776&rft.epage=783&rft.pages=776-783&rft.issn=0741-238X&rft.eissn=1865-8652&rft_id=info:doi/10.1007/s12325-009-0062-1&rft_dat=%3Cproquest_cross%3E734220219%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=734220219&rft_id=info:pmid/19756415&rfr_iscdi=true